$SERA

Aerts Austin sold $4K of SERA

Aerts Austin (Chief Financial Officer) sold 2,037 shares of SERA PROGNOSTICS, INC. (SERA) at $2.01 on 2026-06-11.

Original reporting
SEC EDGAR · Aerts Austin
Published Jun 15, 2026, 8:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 15, 2026, 8:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SERA
Neutral
high confidence
Mentioned
$SERA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SERANeutralLow
01

Why it matters

The newest fact is the CFO’s open-market sale details (shares, price, total value, post-transaction holdings). This can modestly influence retail sentiment but lacks accompanying company fundamentals in the provided text.

02

Market read

Traders may monitor for follow-on insider activity or unusual selling patterns, but the disclosure alone is unlikely to drive a major repricing.

03

What to watch

The article does not state whether the sale was part of a broader pattern, tax event, or diversification; it also notes no pre-arranged 10b5-1 plan, which could increase interpretive uncertainty.

Relevance 3/10Novelty 6/10Timing: Filed 2026-06-15; sale executed 2026-06-11

Background

The article is an SEC Form 4 insider transaction disclosure for SERA PROGNOSTICS, INC.

Company-level read

Ticker impact

$SERANeutralHigh confidence
Context

CFO Aerts Austin filed an open-market sale of 2,037 SERA shares at $2.01 on 2026-06-11, per SEC Form 4.

Expected impact

Low near-term impact; any effect is likely sentiment-driven and short-lived unless followed by additional disclosures.

Evidence & confidence

The filing is an insider open-market sale with no 10b5-1 plan stated and no accompanying company-specific operational/regulatory news in the text.

Market effects

No sector-level read-through; this is a single-company insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for liquidity/tax and may not reflect bearish fundamentals, especially when the transaction is small relative to typical insider holdings.

Key entities

  • SERA PROGNOSTICS, INC.

    Subject of the SEC Form 4 insider transaction; CFO sold shares in an open-market sale.

  • Aerts Austin

    Chief Financial Officer who executed the reported sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SERAMed

Sera (SERA) Q2 2026 Earnings Call Transcript

Sera Prognostics (SERA) reported Q2 2026 revenue of $30,000, up from $17,000 last year, with a net loss of $9.1 million. The company exceeded its payer engagement goal, reaching over 20 states, and launched four commercial partnership programs. Clinical data showed a 22% reduction in NICU admissions and a 30% reduction in neonatal morbidity among first-time mothers. Management expects cash to fund operations through 2029.

$SERAMed

SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

Sera Prognostics (Nasdaq: SERA) reported Q2 2026 revenue of $30,000 versus $17,000 in Q2 2025, with operating expenses of $10.0 million and a net loss of $9.1 million. The company said Illinois Medicaid coverage for PreTRM proteomic tests expanded, it launched a fourth payer partnership program, and PRIME trial data showed reduced NICU admissions in first-time mothers. Cash was about $80.3 million.

$SERAMed

SERA PROGNOSTICS, INC. (SERA): Results of Operations and Financial Condition

SERA PROGNOSTICS, INC. (SERA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS Salt Lake City – August 12, 2026 – Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information t